



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾					
<u>BABY CARE</u>					
US	105	103	1.9%	1.9%	-
Intl	456	426	7.0%	3.3%	3.7%
WW	561	529	6.0%	3.1%	2.9%
<u>ORAL CARE</u>					
US	163	174	-6.3%	-6.3%	-
Intl	228	207	10.1%	5.6%	4.5%
WW	391	381	2.6%	0.2%	2.4%
<u>OTC/NUTRITIONALS</u>					
US	397	542	-26.8%	-26.8%	-
Intl	732	665	10.1%	6.9%	3.2%
WW	1,129	1,207	-6.5%	-8.2%	1.7%
<u>SKIN CARE</u>					
US	426	452	-5.8%	-5.8%	-
Intl	473	468	1.1%	-1.7%	2.8%
WW	899	920	-2.3%	-3.7%	1.4%
<u>WOMEN'S HEALTH</u>					
US	125	146	-14.4%	-14.4%	-
Intl	334	323	3.4%	0.7%	2.7%
WW	459	469	-2.1%	-4.0%	1.9%
<u>WOUND CARE/OTHER</u>					
US	129	143	-9.8%	-9.8%	-
Intl	114	117	-2.6%	-6.9%	4.3%
WW	243	260	-6.5%	-8.4%	1.9%
<u>TOTAL CONSUMER</u>					
US	1,345	1,560	-13.8%	-13.8%	-
Intl	2,337	2,206	5.9%	2.6%	3.3%
WW	3,682	3,766	-2.2%	-4.1%	1.9%

See footnotes on last page

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ^{(2) (5)}					
<u>ACIPHEX/PARIET</u>					
US	109	119	-8.4%	-8.4%	-
Intl	130	141	-7.8%	-8.8%	1.0%
WW	239	260	-8.1%	-8.6%	0.5%
<u>CONCERTA</u>					
US	254	231	10.0%	10.0%	-
Intl	108	98	10.2%	6.3%	3.9%
WW	362	329	10.0%	8.8%	1.2%
<u>DOXIL/CAELYX</u>					
US	64	72	-11.1%	-11.1%	-
Intl	75	8	*	*	20.2%
WW	139	80	73.8%	71.6%	2.2%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>					
US	4	38	-89.5%	-89.5%	-
Intl	123	146	-15.8%	-18.9%	3.1%
WW	127	184	-31.0%	-33.4%	2.4%
<u>LEVAQUIN/FLOXIN</u>					
US	422	363	16.3%	16.3%	-
Intl	12	8	50.0%	44.5%	5.5%
WW	434	371	17.0%	16.9%	0.1%
<u>PREZISTA</u>					
US	126	89	41.6%	41.6%	-
Intl	140	98	42.9%	42.3%	0.6%
WW	266	187	42.2%	41.9%	0.3%
<u>PROCRIT/EPREX</u>					
US	190	290	-34.5%	-34.5%	-
Intl	207	233	-11.2%	-12.3%	1.1%
WW	397	523	-24.1%	-24.6%	0.5%
<u>REMICADE</u>					
US	788	780	1.0%	1.0%	-
US Exports ⁽³⁾	490	400	22.5%	22.5%	-
Intl	7	6	16.7%	16.7%	0.0%
WW	1,285	1,186	8.3%	8.3%	0.0%
<u>RISPERDAL/RISPERIDONE</u>					
US	8	5	60.0%	60.0%	-
Intl	119	133	-10.5%	-14.6%	4.1%
WW	127	138	-8.0%	-12.0%	4.0%
<u>RISPERDAL CONSTA</u>					
US	114	117	-2.6%	-2.6%	-
Intl	290	262	10.7%	9.1%	1.6%
WW	404	379	6.6%	5.5%	1.1%
<u>TOPAMAX</u>					
US	50	57	-12.3%	-12.3%	-
Intl	79	91	-13.2%	-14.4%	1.2%
WW	129	148	-12.8%	-13.5%	0.7%
<u>VELCADE</u>					
US	-	-	-	-	-
Intl	280	261	7.3%	5.6%	1.7%
WW	280	261	7.3%	5.6%	1.7%
<u>OTHER</u>					
US	772	645	19.7%	19.7%	-
Intl	1,098	947	15.9%	12.7%	3.2%
WW	1,870	1,592	17.5%	15.6%	1.9%
TOTAL PHARMACEUTICAL					
US	3,391	3,206	5.8%	5.8%	-
Intl	2,668	2,432	9.7%	7.3%	2.4%
WW	6,059	5,638	7.5%	6.4%	1.1%
MAJOR NEW PHARM PRODUCTS ⁽⁴⁾					
<u>INTELENCE</u>					
US	38	31	22.6%	22.6%	-
Intl	31	24	29.2%	28.3%	0.9%
WW	69	55	25.5%	25.1%	0.4%
<u>INVEGA</u>					
US	69	69	0.0%	0.0%	-
Intl	51	39	30.8%	27.9%	2.9%
WW	120	108	11.1%	10.1%	1.0%
<u>SIMPONI</u>					
US	53	39	35.9%	35.9%	-
Intl	42	3	*	*	-17.4%
WW	95	42	*	*	-1.2%
<u>STELARA</u>					
US	105	56	87.5%	87.5%	-
Intl	61	31	96.8%	94.9%	1.9%
WW	166	87	90.8%	90.1%	0.7%

See footnotes on last page

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾					
<u>CORDIS</u>					
US	242	251	-3.6%	-3.6%	-
Intl	393	421	-6.7%	-9.9%	3.2%
WW	635	672	-5.5%	-7.5%	2.0%
<u>DEPUY</u>					
US	811	814	-0.4%	-0.4%	-
Intl	692	640	8.1%	4.2%	3.9%
WW	1,503	1,454	3.4%	1.7%	1.7%
<u>DIABETES CARE</u>					
US	311	290	7.2%	7.2%	-
Intl	326	307	6.2%	4.9%	1.3%
WW	637	597	6.7%	6.0%	0.7%
<u>ETHICON</u>					
US	516	510	1.2%	1.2%	-
Intl	677	637	6.3%	3.3%	3.0%
WW	1,193	1,147	4.0%	2.3%	1.7%
<u>ETHICON ENDO-SURGERY</u>					
US	471	483	-2.5%	-2.5%	-
Intl	750	685	9.5%	6.0%	3.5%
WW	1,221	1,168	4.5%	2.4%	2.1%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>					
US	265	288	-8.0%	-8.0%	-
Intl	256	237	8.0%	4.1%	3.9%
WW	521	525	-0.8%	-2.5%	1.7%
<u>VISION CARE</u>					
US	256	249	2.8%	2.8%	-
Intl	466	415	12.3%	5.9%	6.4%
WW	722	664	8.7%	4.7%	4.0%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS					
US	2,872	2,886	-0.5%	-0.5%	-
Intl	3,560	3,341	6.6%	3.0%	3.6%
WW	6,432	6,227	3.3%	1.3%	2.0%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Included in Other

(5) Prior year amounts have been reclassified to conform to current presentation